Daxor to Showcase How BVA Provides the Objective Plasma and Red Blood Cell Data Needed to Target Dysautonomia Therapy

Oak Ridge, TN, July 07, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting for the first time at the 14th Annual Dysautonomia International Conference. Daxor will feature its FDA-cleared next-generation rapid, lightweight, lab-based Blood Volume Analyzer (BVA^™). The premier global event for autonomic disorders will take place from July 9–12, 2026, at The Woodlands Marriott Waterway Hotel & Convention Center in The Woodlands, Texas.

This year’s conference theme, "Piece by Piece: Building the Future of Dysautonomia Care," brings together the world’s leading physicians, researchers, clinicians, and patient advocates. Daxor’s presence underscores a major paradigm shift in autonomic medicine: shifting away from subjective symptom tracking and moving toward objective, precision data.

“For too long, dysautonomia patients have faced an uphill battle due to the limitations of traditional diagnostics," said John L. Jefferies, MD, MPH, MBA, Daxor's Chief Medical Officer. "Standard assessments like peripheral hematocrit, blood pressure, or heart rate frequently fail to reflect a patient's true intravascular status. BVA replaces clinical guesswork with objective data. By obtaining accurate baselines for both plasma and red blood cell volumes, physicians can deliver a truly targeted, data-driven therapeutic response with clinical precision.”

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.

For more information, please visit our website at Daxor.com.

Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com